NCT02114229 2026-03-17
SJATRT
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
Clinical Trials
23 trialsNCT04555837 2025-05-20
Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01848067 2025-05-04
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Thomas Jefferson University
Phase 1/2 Completed
NCT02186509 2025-04-30
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Thomas Jefferson University
Phase 1 Completed
NCT04085315 2024-06-10
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
University of California, San Francisco
Phase 1 Recruiting
NCT04479306 2024-06-04
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02293005 2022-10-04
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01924260 2022-08-02
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
University of California, Davis
Phase 1 Completed
NCT02530619 2021-05-26
Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
Northwestern University
Phase NA Unknown
NCT02560025 2020-05-05
Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML
Massachusetts General Hospital
Phase 2 Completed
NCT01601535 2019-07-31
Study of MLN8237 in Combination With Irinotecan and Temozolomide
New Approaches to Neuroblastoma Therapy Consortium
Phase 1/2 Completed
NCT01639911 2019-07-22
Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
University of Illinois at Chicago
Phase 1 Completed
NCT02109328 2019-04-11
Alisertib in Chemotherapy-pretreated Urothelial Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT01923337 2019-01-04
Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
University of California, Davis
Phase 1 Completed
NCT01540682 2018-08-29
MLN8237 in Head and Neck Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT02780011 2018-07-27
AD3LE
The Methodist Hospital Research Institute
Phase 1 Withdrawn
NCT01812005 2018-06-06
Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT01471964 2018-05-17
Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT01799278 2018-01-23
A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
Weill Medical College of Cornell University
Phase 2 Completed
NCT01677559 2018-01-11
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Washington University School of Medicine
Phase 1 Completed
NCT02700022 2017-11-20
A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT02812056 2017-03-27
Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT01034553 2016-05-25
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed